ARTICLE | Clinical News
AIR DNase: Completed Ph II enrollment
December 30, 2016 1:45 AM UTC
Protalix completed enrollment of 15 patients switching over from Pulmozyme dornase alfa in an open-label, Israeli Phase II trial evaluating 2.5 mg inhaled AIR DNase once daily for 28 days....
BCIQ Company Profiles